With inflation hitting yet another record-breaking high—9.1% at the time of publication—hospitals and health systems continue to contend with challenging supply chain disruptions that force leaders into a constant state of putting out fires.
Supply chain issues are not new. But instead of having time to plan ahead and implement sustainable solutions, leaders find themselves always having to devote their energy towards solving the next problem. Currently, drug shortages are an immediate concern.
The July issue of OR Manager covered the unprecedent shortage of iodinated contrast media and the ripple effect it had on providers, associations, and policy makers. Unfortunately, that was just one example of the supply of essential medication drying out.
“Drug shortages have been a persistent problem in the US,” Valerie Jensen, USPHS (Ret), associate director, CDER Drug Shortage Staff, at the Food and Drug Administration (FDA), said during the July 14 Becker’s Healthcare webinar, titled “Strengthening the healthcare supply chain in a post-pandemic world.”
Challenges to do with shortages were amplified with the pandemic, Jansen added, noting that “communication with industry and other stakeholders has been key” in addressing these challenges.
“One of the things we’re learning is there’s a real direct link between healthcare security, national security, and the market circuit,” said Jonathan Kimball, vice president of trade, international affairs, and strategic initiatives at the Association for Accessible Medicines, during the same Becker’s webinar.
The pandemic caused supply chains across the global economy to be upended. “Governments responded to that in a number of ways,” Kimball said. “Some of them implemented export controls and increased calls for local investment to respond to concerns that the global supply chain was vulnerable to disruption. We saw this especially in the pharmaceutical market.”
According to Kimball, policy makers predicted massive shortages for key medicines, “and that did happen.” A big reason for these shortages is an “erosion” of the price of essential medicines because of what key players are willing to pay for them, he added.
Beverly K. Philip, MD, FACA, FASA, immediate past president of the American Society of Anesthesiologists (ASA), agrees that economics is a big factor in these disruptions. “For the most part, these are inexpensive drugs,” she says during an interview with OR Manager. “There’s very little profit in them, so it’s hard to invest in the technology and in the manufacturing to get them, not only in the US but in the international supply chain for most of our active ingredients.”
When the ingredients do arrive from China or India, she explains, “we have to put them together into finished products. Because of these economic problems, companies are being asked to charge as little as possible by hospitals that are strained economically.”
“There is currently a serious problem with drug shortages in anesthesiology,” says Dr Philip. “This impacts the entirety of anesthesiology practice. In terms of the OR, for general anesthesia, there are two major drugs in shortage repeatedly: propofol and ketamine.”
Outside the OR, the shortage is more apparent. “Sedation drugs are in short order,” she adds. “We’re short of drugs for laboring women, for pain management, and even in intensive care.”
At the start of the pandemic, patients were still able to access essential medication because of the availability of generic brand options, which make up 92% of pharmaceutical prescriptions, said Kimball during Becker’s webinar. “Policy makers quickly realized that the generic industry had strong contingency plans in place to fight these challenges,” he said.
According to Kimball, generic brand companies learned how to manage their supply diversity from previous disruptions caused by international unrest and past natural disasters. “These contingency plans and stock piles were instrumental in ensuring the continuity of supply,” he said, adding that since the pandemic started, “these plans have strengthened even more with companies demanding greater certainty in their own supply chains and extending the volume of their own stock piles.”
“What we need to change going forward as we prepare for the next pandemic, or the next healthcare crisis, is how the US healthcare system values essential medicines,” Kimball continued. “One of the things we as an industry are doing better is, we now have leaders of supply chain coming together to talk about the key policy issues we are facing. We have greater coordination around policy challenges as well as solutions we can work on.”
Dr Philip agrees; just stocking up extra drugs in the basement will not suffice. “These are systematic problems, and what they need are system-wide answers,” she says. “If we can predict that something’s going to be in shortage, we need to be able to prepare alternative sources, alternative drugs, and targeted use of whatever supply we have.”
That type of system-wide response requires coordination and collaboration across multiple agencies, she adds. “ASA has been successfully advocating for real legislation on drug shortages to be improved. ASA’s been partnering with other major actors, particularly the American Society of Health-System Pharmacists and the FDA, to highlight these faults to the government. We need to help the government develop legislative and regulatory assets to ensure that the US has safe access to high-quality medicines because it is a matter of national security,” she says.
Cost savings is a theme of this month’s issue. With the financial strains hospitals and health systems have been under because of the aforementioned inflation and rising costs associated with these disruptions and shortages, facilities are desperate to find ways to cut expenses and recover revenue.
This issue’s stories cover the efficiencies and cost savings three major health systems achieved through optimizing their instrument trays (cover story); the financial burden of unprofessional behavior from hospital staff, particularly physicians, when it is left unchecked (pp 14–17); and the operational improvements associated with robust electronic health record and block scheduling systems (pp 20–23).
Three other articles round out this month: the next installment of the Leadership Series, featuring best practices when mentoring and working legislatively from Kay Ball, PhD, RN, CNOR, CMLSO, FAAN (cover story); a look into how the occurrence of miscounts and lost sharps is recollected differently by individual OR personnel in the room (pp 18–19); and a crash course on the nationally recognized accreditation from the Accreditation Association for Ambulatory Health Care (pp 24–27).
Future OR Manager articles will delve into other cost reduction strategies, including further coverage of drug shortages and exploring tips for single-use device reprocessing, ways to mitigate unprofessional behavior, cross-specialty specialization, contracts between ambulatory surgery centers and anesthesia providers, and return on technology-driven investments. Stay tuned!